Zolpidem

Ambien, Edluar, Intermezzo, Tovalt Odt, Zolpimist (zolpidem) is a small molecule pharmaceutical. Zolpidem was first approved as Ambien on 1992-12-16. It is used to treat sleep initiation and maintenance disorders in the USA. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit alpha-1. In addition, it is known to target gamma-aminobutyric acid receptor subunit alpha-2 and gamma-aminobutyric acid receptor subunit alpha-3. Ambien's patents are valid until 2032-08-07 (FDA).